NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Equality impact assessment

IPG695 Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplantation

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

Briefing

1.	Have any potential equality issues been identified during the briefing process (development of the brief or discussion at the committee meeting), and, if so, what are they?
The majority of lung transplants are given to people under 65 years and there is no data on gender differences. Higher socioeconomic deprivation is associated with shorter survival in transplant patients. Patients with long term severe respiratory conditions including cystic fibrosis, pulmonary hypertension, COPD, idiopathic pulmonary fibrosis and end stage chronic lung disease requiring lung transplantation are likely to be covered under the Disability and Equality act 2010. Some religious groups may not support the principles of organ donation and transplantation.	

2.	What is the preliminary view as to what extent these potential equality issues need addressing by the committee? (If there are exclusions listed in the brief (for example, populations, treatments or settings), are these justified?)
This was not thought to have an impact on the assessment of the procedure. No exclusions were applied.	

© NICE 2021. All rights reserved. Subject to Notice of rights

3.	Has any change to the brief (such as additional issues raised during the committee meeting) been agreed to highlight potential equality issues?
No	

4.	Have any additional stakeholders related to potential equality issues been identified during the committee meeting, and, if so, have changes to the stakeholder list been made?'
No	

Kevin Harris

Approved by Programme Director and Clinical Advisor for IP

Date: 06/04/2021

Consultation

1.	Have the potential equality issues identified during the briefing process been addressed by the committee, and, if so, how?
No specific data relating to [potential issues mentioned earlier] was identified in the literature presented in the overview.	

2.	Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the committee addressed these?
No	

3.	Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

© NICE 2021. All rights reserved. Subject to Notice of rights

No

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No	

5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
Not applicable	

6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligation to promote equality?
Not applicable	

7.	Have the committee's considerations of equality issues been described in the consultation document, and, if so, where?
No	

Kevin Harris

Approved by Programme Director and Clinical Advisor for IP

Date: 06/04/2021

© NICE 2021. All rights reserved. Subject to Notice of rights

Final interventional procedures document

1.	Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?
No	

2.	If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
Not applicable	

3.	If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
Not applicable	

4.	If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
Not applicable	

© NICE 2021. All rights reserved. Subject to Notice of rights

5.	Have the committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?
No	

Kevin Harris

Approved by Programme Director and Clinical Advisor for IP

Date: 06/04/2021

© NICE 2021. All rights reserved. Subject to Notice of rights